nach oben

Die Urologie

Erschienen in:

27.03.2018 | Antiemetische Therapie | Leitthema

Chemotherapieinduzierte Nausea und Emesis

Aktuelle Empfehlungen zur Prophylaxe

verfasst von: E. Storz, J. E. Gschwend, M. Retz

Erschienen in: Die Urologie | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die chemotherapieinduzierte Nausea und Emesis (CINE) gehören zu den häufigsten Nebenwirkungen der Zytostatikatherapie und stellen bei der Behandlung onkologischer Patienten eine große Herausforderung dar. Eine korrekte, leitliniengerechte antiemetische Prophylaxe ist daher unerlässlich und trägt wesentlich zum Behandlungserfolg bei. Diese Übersichtsarbeit fasst die aktuellen Empfehlungen der „Multinational Association of Supportive Care in Cancer“ (MASCC) und „European Society of Medical Oncology“ (ESMO), der „American Society for Clinical Oncology“ (ASCO), des „National Comprehensive Cancer Network“ (NCCN) sowie der S3-Leitlinie „Supportive Therapie“ vom „Leitlinienprogramm Onkologie“ zur Prophylaxe der CINE verständlich zusammen und soll deren Anwendung in der täglichen Routine erleichtern.

AOP (2016) Fachinformation zu CANEMES 1 mg Kaps. http://sr001017043/detailinfo.php?ID=3348522200. Zugegriffen: 02.01.18

Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2017) Leitlinienprogramm Onkologie: S3-Leitlinie Supportive Therapie bei onkologischen PateintInnen, Langversion 1.1, April 2017, AWMF Registrierungsnummer 032/054OL. http://leitlinienprogramm-onkologie.de/. Zugegriffen: 9. Dez. 2017

Aapro M, Rugo H, Rossi G et al (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328–1333CrossRefPubMedPubMedCentral

Aapro MS, Molassiotis A, Olver I (2005) Anticipatory nausea and vomiting. Support Care Cancer 13:117–121CrossRefPubMed

Bymaster FP, Calligaro DO, Falcone JF et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87–96CrossRefPubMed

Coates A, Abraham S, Kaye SB et al (1983) On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203–208CrossRefPubMed

Cohen L, de Moor CA, Eisenberg P et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497–503CrossRefPubMed

Dando TM, Perry CM (2004) Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 64:777–794CrossRefPubMed

Ettinger DS, Berger MJ, Aston J et al (2017) NCCN guidelines; Antiemesis, version 2.2017. http://nccn.org. Zugegriffen: 9. Dez. 2017

10.

Geling O, Eichler HG (2005) Should 5‑hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289–1294CrossRefPubMed

11.

Gralla RJ, Bosnjak SM, Hontsa A et al (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25:1333–1339CrossRefPubMedPubMedCentral

12.

Gralla RJ, Itri LM, Pisko SE et al (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905–909CrossRefPubMed

13.

Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971–2994CrossRefPubMed

14.

Grunberg S, Chua D, Maru A et al (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASE. J Clin Oncol 29:1495–1501CrossRefPubMed

15.

Grunberg SM (2004) Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment—how are we doing? J Support Oncol 2:1–12PubMed

16.

Grunberg SM, Deuson RR, Mavros P et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268CrossRefPubMed

17.

Grunberg SM, Osoba D, Hesketh PJ et al (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update. Support Care Cancer 13:80–84CrossRefPubMed

18.

Hesketh PJ, Aapro M, Street JC et al (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18:1171–1177CrossRefPubMed

19.

Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112–4119CrossRefPubMed

20.

Hesketh PJ, Kris MG, Basch E et al (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240–3261CrossRefPubMed

21.

Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103–109CrossRefPubMed

22.

Jordan K, Gralla R, Jahn F et al (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197–202CrossRefPubMed

23.

Kamen C, Tejani MA, Chandwani K et al (2014) Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol 722:172–179CrossRefPubMed

24.

Licup N (2010) Olanzapine for nausea and vomiting. Am J Hosp Palliat Care 27:432–434CrossRefPubMed

25.

Navari RM (2014) Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol 722:180–186CrossRefPubMed

26.

Navari RM (2015) Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther 9:155–161PubMed

27.

Navari RM, Einhorn LH, Passik SD et al (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 13:529–534CrossRefPubMed

28.

Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188–195CrossRefPubMed

29.

Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655–1663CrossRefPubMed

30.

Perwitasari DA, Gelderblom H, Atthobari J et al (2011) Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. Int J Clin Pharm 33:33–43CrossRefPubMedPubMedCentral

31.

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3098CrossRefPubMed

32.

Raftopoulos H, Cooper W, O’Boyle E et al (2015) Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Support Care Cancer 23:723–732CrossRefPubMed

33.

Rapoport B, Chua D, Poma A et al (2015) Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer 23:3281–3288CrossRefPubMed

34.

Rapoport BL, Chasen MR, Gridelli C et al (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 16:1079–1089CrossRefPubMed

35.

Rapoport BL, Jordan K, Boice JA et al (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423–431CrossRefPubMed

36.

Roila F, Molassiotis A, Herrstedt J et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(v119):v133

37.

Schwartzberg L, Barbour SY, Morrow GR et al (2014) Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer 22:469–477CrossRefPubMed

38.

Shadle CR, Lee Y, Majumdar AK et al (2004) Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 44:215–223CrossRefPubMed

39.

Spartinou A, Nyktari V, Papaioannou A (2017) Granisetron: a review of pharmacokinetics and clinical experience in chemotherapy induced—nausea and vomiting. Expert Opin Drug Metab Toxicol 13:1289–1297CrossRefPubMed

40.

Tafelski S, Hauser W, Schafer M (2016) Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting—a systematic review of systematic reviews. Schmerz 30:14–24CrossRefPubMed

41.

Tageja N, Groninger H (2016) Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines. Postgrad Med J 92:34–40CrossRefPubMed

42.

Warr D (2014) Prognostic factors for chemotherapy induced nausea and vomiting. Eur J Pharmacol 722:192–196CrossRefPubMed

Titel: Chemotherapieinduzierte Nausea und Emesis
Aktuelle Empfehlungen zur Prophylaxe
verfasst von: E. Storz
J. E. Gschwend
M. Retz
Publikationsdatum: 27.03.2018
Verlag: Springer Medizin
Schlagwörter: Antiemetische Therapie
Zytostatische Therapie
Übelkeit
Erbrechen
Olanzapin
Glucocorticoide
Dexamethason
Erschienen in: Die Urologie / Ausgabe 5/2018
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI: https://doi.org/10.1007/s00120-018-0606-6

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Chemotherapieinduzierte Nausea und Emesis

Aktuelle Empfehlungen zur Prophylaxe

Zusammenfassung

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

Supportive Therapie, „best supportive care“ und Palliativmedizin

Knoten an der Vorhaut: Wie lautet Ihre Diagnose?

Randomisierte Studien: So verlieren Sie weniger Patienten

Nebenwirkungsprofil der Immun-Checkpoint-Inhibitoren

Ungerechtfertigte Empfehlungen zur ketogenen Diät

AUO

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie